Related Experiment Video

Updated: Apr 20, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.6K

A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy

Salim Chahin1, Joseph R Berger2

  • 1Multiple Sclerosis Division of the Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, 3W Gates, Philadelphia, PA, USA. salim.chahin@uphs.upenn.edu.

Journal of Neurovirology
|November 19, 2014
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a rare brain infection, is linked to immunosuppressive drugs. This study proposes a new drug classification system to better assess PML risks for clinicians and patients.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Immunology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic central nervous system infection caused by the JC virus.
  • PML is increasingly associated with immunosuppressive and biologic agents, posing a significant clinical challenge.
  • Quantifying PML risk is difficult due to complex pathogenesis and confounding factors.

Purpose of the Study:

  • To update the understanding of PML associations with various biologic and immunosuppressive agents.
  • To propose an expanded classification system for stratifying PML risk.
  • To provide clinicians and patients with information for informed decision-making regarding immunologic agents.

Main Methods:

  • Review of current literature on PML and its association with immunosuppressive/biologic agents.
  • Development of a novel drug classification system based on PML risk and latency.
  • Analysis of common agents with known PML associations.

Main Results:

  • Identification of three distinct drug classes based on PML risk, infection latency, and underlying illness.
  • Updated review of agents commonly associated with PML.
  • Exploration of risk mitigation strategies.

Conclusions:

  • The proposed classification system aims to clarify PML risk associated with different immunologic agents.
  • Understanding these risks is crucial for managing patients on immunosuppressive therapies.
  • This work supports informed clinical and patient decision-making in the evolving landscape of immunologic treatments.
Keywords:
EfalizumabMycophenolate mofetilNatalizumabProgressive multifocal leukoencephalopathyRituximab

More Related Videos

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

19.0K
Mouse Models of Periventricular Leukomalacia06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

30.6K

Related Concept Videos

Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
5
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.5K
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
9
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
4
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
6